Affidea Group appoints Frans van Houten to its Supervisory Board

– NETHERLANDS, The Hague –  Affidea Group, the leading pan-European provider of integrated healthcare including advanced diagnostics, out-of-hospital services, and Centres of Excellence, today announced the appointment of Frans van Houten to its Supervisory Board as a Non-Executive Director.

Michal Chalaczkiewicz, Chairman of Affidea’s Supervisory Board and Investment Partner at GBL, added: “We are delighted to welcome Frans van Houten to Affidea’s Supervisory Board, joining the other distinguished members. His appointment represents a significant addition, embodying GBL’s commitment as a shareholder in Affidea. We are looking forward to working alongside Frans and leveraging his expertise as we build the future path of this exciting journey together with the teams at Affidea and GBL”.

About Frans van Houten

A recognized visionary in healthcare innovation and technology sectors, Frans van Houten will leverage his leadership skills and insights to significantly enhance Affidea’s aspirations for growth and digital innovation. He spent nearly 30 years at Royal Philips and is highly regarded for his strategic insights. In his role as CEO, he transformed the organization from a diversified conglomerate into a focused health technology solutions company. This transformation doubled Philips’ organic growth and profitability. Additionally, Frans van Houten currently serves on Novartis’ Board of Directors, contributing to one of the world’s foremost pharmaceutical companies, and also advises the private equity sector.

Frans van Houten said: “Affidea stands as a fast-growth European healthcare champion renowned for its innovative spirit—a spirit I am thrilled to support. The company’s longstanding dedication to enhancing every aspect of the care pathway and improving patient outcomes through technological innovation resonates with my own. My commitment is to the seamless integration of cutting-edge, patient-centric solutions that promise quality, personalised and efficient healthcare experiences throughout the care continuum. I look forward to collaborating with the Supervisory Board and management team to unlock Affidea’s complete growth potential.”

Fran van Houten’s expertise in healthcare innovation and advanced technologies is in harmony with Affidea’s ambitions to develop connected, patient-centric solutions, including telehealth services and wearable technologies, aimed at enriching the entire care pathway. This strategic direction will enable the company’s medical professionals to access and respond to patients’ needs remotely, thus enhancing healthcare outcomes.

About Affidea Group

Affidea Group is Europe’s leading integrated healthcare provider, including advanced diagnostics, out-of-hospital services, and Centres of Excellence in orthopedics and cancer care. Founded in 1991, the company operates more than 340 medical centers in 15 countries, serving over 13 million patients annually. Due to its high standards in patient safety, Affidea is the most awarded provider of medical imaging services in Europe. More than 90% of the award-winning centers with 5 stars on the Eurosafe Wall of Stars, accredited by the European Society of Radiology in Europe, are Affidea centers.

Affidea is majority-owned by GBL (Groupe Bruxelles Lambert), an established investment holding company committed to strong governance and leadership across its portfolio of businesses. GBL is a leading investor in Europe, focused on long-term value creation and relying on a stable and supportive family shareholder base.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.